Markets

Our first path to market is in skin cancer detection.

​

Twenty percent of Americans will receive a skin cancer diagnosis before the age of 70; many more will go through a biopsy procedure for suspected skin cancer.

​

The roughly 80% of skin biopsies in the United States do not result in a cancer diagnosis, adding unnecessary cost to the healthcare system. 

​

The IRMedtek fast cancer detection probe increases early accuracy detection, improves efficiency, and reduces the unnecessary number of biopsies. It provides immediate information at a primary care visit.

​

The platform offers other paths to market with devices very similar to the initial product. These include cervical, oral, and anal cancers along with intraoperative and endoscopic procedures.